CL2023003020A1 - Heterociclos con sustitución amino para tratar cánceres con mutaciones de egfr - Google Patents

Heterociclos con sustitución amino para tratar cánceres con mutaciones de egfr

Info

Publication number
CL2023003020A1
CL2023003020A1 CL2023003020A CL2023003020A CL2023003020A1 CL 2023003020 A1 CL2023003020 A1 CL 2023003020A1 CL 2023003020 A CL2023003020 A CL 2023003020A CL 2023003020 A CL2023003020 A CL 2023003020A CL 2023003020 A1 CL2023003020 A1 CL 2023003020A1
Authority
CL
Chile
Prior art keywords
amino
treat cancers
egfr mutations
substituted heterocycles
compounds
Prior art date
Application number
CL2023003020A
Other languages
English (en)
Inventor
Baudouin Gerard
Joshua Courtney Horan
Scot Richard Mente
Henry Efrem Pelish
Matthew D Shair
Anupong Tangpeerachaikul
Kristin Lynne Andrews
Yuting Sun
Original Assignee
Nuvalent Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nuvalent Inc filed Critical Nuvalent Inc
Publication of CL2023003020A1 publication Critical patent/CL2023003020A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se describen compuestos heteroaromáticos con sustitución amino tales como 4-amino-quinazolinas, sales farmacéuticamente aceptables de los compuestos y composiciones farmacéuticas de estos. También se describen los métodos para tratar o prevenir el cáncer con los compuestos heteroaromáticos con sustitución amino, sales farmacéuticamente aceptables de los compuestos, y composiciones farmacéuticas de estos.
CL2023003020A 2021-04-13 2023-10-10 Heterociclos con sustitución amino para tratar cánceres con mutaciones de egfr CL2023003020A1 (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202163174177P 2021-04-13 2021-04-13
US202163239089P 2021-08-31 2021-08-31
US202163242837P 2021-09-10 2021-09-10
US202163292605P 2021-12-22 2021-12-22

Publications (1)

Publication Number Publication Date
CL2023003020A1 true CL2023003020A1 (es) 2024-03-22

Family

ID=81392726

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003020A CL2023003020A1 (es) 2021-04-13 2023-10-10 Heterociclos con sustitución amino para tratar cánceres con mutaciones de egfr

Country Status (12)

Country Link
US (1) US20220363696A1 (es)
EP (1) EP4323356A1 (es)
JP (1) JP2024516371A (es)
KR (1) KR20230170039A (es)
AU (1) AU2022257621A1 (es)
BR (1) BR112023021111A2 (es)
CA (1) CA3213079A1 (es)
CL (1) CL2023003020A1 (es)
IL (1) IL306100A (es)
PE (1) PE20240327A1 (es)
TW (1) TW202309022A (es)
WO (1) WO2022221227A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202214641A (zh) 2020-06-30 2022-04-16 美商艾瑞生藥股份有限公司 Ｈｅｒ２突變抑制劑
PE20240327A1 (es) * 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr
WO2023081637A1 (en) 2021-11-02 2023-05-11 Enliven Therapeutics, Inc. Fused tetracyclic quinazoline derivatives as inhibitors of erbb2
CN117384162A (zh) * 2022-05-17 2024-01-12 浙江文达医药科技有限公司 选择性her2抑制剂
WO2024027695A1 (zh) * 2022-08-04 2024-02-08 微境生物医药科技(上海)有限公司 作为her2抑制剂的化合物

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861A (en) 1848-10-17 Locking umbrella and parasol
US5863A (en) 1848-10-17 Matthias p
US949A (en) 1838-09-27 Improvement in roller cotton-gins for ginning long-staple and other kinds of cotton
US510A (en) 1837-12-07 soeel
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
US4172896A (en) 1978-06-05 1979-10-30 Dainippon Pharmaceutical Co., Ltd. Methane-sulfonamide derivatives, the preparation thereof and composition comprising the same
GB8827305D0 (en) 1988-11-23 1988-12-29 British Bio Technology Compounds
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5455258A (en) 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5863949A (en) 1995-03-08 1999-01-26 Pfizer Inc Arylsulfonylamino hydroxamic acid derivatives
DK0821671T3 (da) 1995-04-20 2001-04-23 Pfizer Arylsulfonylhydroxamsyrederivater som MMP- og TNF-inhibitorer
ATE225343T1 (de) 1995-12-20 2002-10-15 Hoffmann La Roche Matrix-metalloprotease inhibitoren
JP3195756B2 (ja) 1996-07-04 2001-08-06 公子 吉水 潤滑補助体
ATE217315T1 (de) 1996-07-18 2002-05-15 Pfizer Matrix metalloprotease-inhibitoren auf basis von phosphinsäuren
IL128189A0 (en) 1996-08-23 1999-11-30 Pfizer Arylsulfonylamino hydroxamic acid derivatives
ATE272640T1 (de) 1997-01-06 2004-08-15 Pfizer Cyclische sulfonderivate
PT977733E (pt) 1997-02-03 2003-12-31 Pfizer Prod Inc Derivados de acido arilsulfonilamino-hidroxamico
AU5493598A (en) 1997-02-07 1998-08-26 Pfizer Inc. N-hydroxy-beta-sulfonyl-propionamide derivatives and their use as inhibitors of matrix metalloproteinases
BR9807678A (pt) 1997-02-11 2000-02-15 Pfizer Derivados de ácidos arilsulfonil-hidroxâmicos
CN1229110C (zh) 1997-07-29 2005-11-30 阿尔康实验室公司 含半乳甘露聚糖聚合物和硼酸盐的眼用组合物
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
GB9801690D0 (en) 1998-01-27 1998-03-25 Pfizer Ltd Therapeutic agents
JP2002501892A (ja) 1998-01-29 2002-01-22 セプラコア インコーポレーテッド 光学的に純粋な（−）−ビュープロピオンの薬学的使用
PA8469401A1 (es) 1998-04-10 2000-05-24 Pfizer Prod Inc Derivados biciclicos del acido hidroxamico
PA8469501A1 (es) 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
EP1143957A3 (en) 1998-12-16 2002-02-27 Warner-Lambert Company Treatment of arthritis with mek inhibitors
IL129299A0 (en) 1999-03-31 2000-02-17 Mor Research Applic Ltd Monoclonal antibodies antigens and diagnosis of malignant diseases
US8889112B2 (en) 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
CA3016482A1 (en) 1999-11-30 2001-06-07 Mayo Foundation For Medical Education And Research B7-h1, a novel immunoregulatory molecule
SI1301472T1 (sl) 2000-07-19 2014-05-30 Warner-Lambert Company Llc Oksigenirani estri 4-jodo fenilamino benzihidroksamskih kislin
US6995162B2 (en) 2001-01-12 2006-02-07 Amgen Inc. Substituted alkylamine derivatives and methods of use
CN100522967C (zh) 2002-02-01 2009-08-05 阿里亚德基因治疗公司 含磷化合物及其应用
EP2308861B1 (en) 2002-03-08 2017-03-01 Eisai R&D Management Co., Ltd. Macrocyclic compounds useful as pharmaceuticals
PT2275102E (pt) 2002-03-13 2015-10-27 Array Biopharma Inc Derivados de benzimidazole alquilado n3 como inibidores de mek
IL149820A0 (en) 2002-05-23 2002-11-10 Curetech Ltd Humanized immunomodulatory monoclonal antibodies for the treatment of neoplastic disease or immunodeficiency
EP3287144A1 (en) 2002-07-03 2018-02-28 ONO Pharmaceutical Co., Ltd. Immunopotentiating compositions
CN101899114A (zh) 2002-12-23 2010-12-01 惠氏公司 抗pd-1抗体及其用途
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
BRPI0413381A (pt) 2003-08-07 2006-10-17 Allergan Inc composições para liberação de compostos terapêuticos nos olhos e processos para fabricação e uso das mesmas
US20050059744A1 (en) 2003-09-12 2005-03-17 Allergan, Inc. Methods and compositions for the treatment of pain and other alpha 2 adrenergic-mediated conditions
CA2970873C (en) 2005-05-09 2022-05-17 E. R. Squibb & Sons, L.L.C. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
CN104356236B (zh) 2005-07-01 2020-07-03 E.R.施贵宝&圣斯有限责任公司 抗程序性死亡配体1(pd-l1)的人单克隆抗体
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
DE602006021645D1 (de) * 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
US9244059B2 (en) 2007-04-30 2016-01-26 Immutep Parc Club Orsay Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP1987839A1 (en) 2007-04-30 2008-11-05 I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease
EP3222634A1 (en) 2007-06-18 2017-09-27 Merck Sharp & Dohme B.V. Antibodies to human programmed death receptor pd-1
PE20140100A1 (es) 2007-09-12 2014-02-12 Genentech Inc Combinaciones de compuestos inhibidores de fosfoinositida 3-quinasa y agentes quimioterapeuticos
EP2044949A1 (en) 2007-10-05 2009-04-08 Immutep Use of recombinant lag-3 or the derivatives thereof for eliciting monocyte immune response
US8354528B2 (en) 2007-10-25 2013-01-15 Genentech, Inc. Process for making thienopyrimidine compounds
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
AR072999A1 (es) 2008-08-11 2010-10-06 Medarex Inc Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos
KR20110074850A (ko) 2008-08-25 2011-07-04 앰플리뮨, 인크. Ｐｄ-１ 길항제 및 그의 사용 방법
CA2736829C (en) 2008-09-12 2018-02-27 Isis Innovation Limited Pd-1 specific antibodies and uses thereof
AU2009296392B2 (en) 2008-09-26 2016-06-02 Dana-Farber Cancer Institute, Inc. Human anti-PD-1, PD-L1, and PD-L2 antibodies and uses therefor
BRPI0920765A2 (pt) 2008-10-29 2015-08-18 Deciphera Pharmaceuticals Llc Amidas de cilopropano e análogos que exibem atividades anticâncer e antiproliferativas
PE20120341A1 (es) 2008-12-09 2012-04-24 Genentech Inc Anticuerpos anti-pd-l1 y su uso para mejorar la funcion de celulas t
KR101573109B1 (ko) 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
WO2011066342A2 (en) 2009-11-24 2011-06-03 Amplimmune, Inc. Simultaneous inhibition of pd-l1/pd-l2
CA2791930A1 (en) 2010-03-11 2011-09-15 Kerry Louise Tyson Pd-1 antibody
KR101846590B1 (ko) 2010-06-11 2018-04-09 교와 핫꼬 기린 가부시키가이샤 항 ｔｉｍ-3 항체
WO2011159877A2 (en) 2010-06-18 2011-12-22 The Brigham And Women's Hospital, Inc. Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions
US8907053B2 (en) 2010-06-25 2014-12-09 Aurigene Discovery Technologies Limited Immunosuppression modulating compounds
CA2833636A1 (en) 2011-04-20 2012-10-26 Amplimmune, Inc. Antibodies and other molecules that bind b7-h1 and pd-1
WO2013006490A2 (en) 2011-07-01 2013-01-10 Cellerant Therapeutics, Inc. Antibodies that specifically bind to tim3
AU2012288413B2 (en) 2011-07-24 2016-10-13 Curetech Ltd. Variants of humanized immunomodulatory monoclonal antibodies
LT2785375T (lt) 2011-11-28 2020-11-10 Merck Patent Gmbh Anti-pd-l1 antikūnai ir jų panaudojimas
CN115093480A (zh) 2012-05-31 2022-09-23 索伦托药业有限公司 与pd-l1结合的抗原结合蛋白
UY34887A (es) 2012-07-02 2013-12-31 Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos
ES2848052T3 (es) 2012-08-03 2021-08-05 Dana Farber Cancer Inst Inc Anticuerpos de unión dual anti-PD-L1 y PD-L2 de agente individual y métodos de uso
WO2014055897A2 (en) 2012-10-04 2014-04-10 Dana-Farber Cancer Institute, Inc. Human monoclonal anti-pd-l1 antibodies and methods of use
AR093984A1 (es) 2012-12-21 2015-07-01 Merck Sharp & Dohme Anticuerpos que se unen a ligando 1 de muerte programada (pd-l1) humano
AU2014230741B2 (en) 2013-03-15 2017-04-13 Glaxosmithkline Intellectual Property Development Limited Anti-LAG-3 binding proteins
EP2992017B1 (en) 2013-05-02 2020-11-18 AnaptysBio, Inc. Antibodies directed against programmed death-1 (pd-1)
JP6563906B2 (ja) 2013-05-31 2019-08-21 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． Ｐｄ−１に結合する抗原結合蛋白質
WO2014209804A1 (en) 2013-06-24 2014-12-31 Biomed Valley Discoveries, Inc. Bispecific antibodies
AU2013400609B9 (en) 2013-09-13 2020-03-05 Beigene Switzerland Gmbh Anti-PD1 antibodies and their use as therapeutics and diagnostics
AU2014339900B2 (en) 2013-10-25 2019-10-24 Dana-Farber Cancer Institute, Inc. Anti-PD-L1 monoclonal antibodies and fragments thereof
WO2015081158A1 (en) 2013-11-26 2015-06-04 Bristol-Myers Squibb Company Method of treating hiv by disrupting pd-1/pd-l1 signaling
CR20160319A (es) 2013-12-12 2016-11-08 Jiangsu Hengrui Medicine Co Anticuerpo pd-1, fragmento de union al antigeno de este y uso médico de este
JP2017509319A (ja) 2014-01-15 2017-04-06 カドモン コーポレイション，リミティド ライアビリティ カンパニー 免疫調節剤
TWI680138B (zh) 2014-01-23 2019-12-21 美商再生元醫藥公司 抗ｐｄ-ｌ１之人類抗體
TWI681969B (zh) 2014-01-23 2020-01-11 美商再生元醫藥公司 針對ｐｄ-１的人類抗體
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
EA201691361A1 (ru) 2014-01-28 2016-12-30 Бристол-Маерс Сквибб Компани Антитела к lag-3 для лечения гематологических злокачественных опухолей
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
ME03558B (me) 2014-03-14 2020-07-20 Novartis Ag Molekuli anti-lag-3 antiтela i njihove upotrebe
US9885721B2 (en) 2014-05-29 2018-02-06 Spring Bioscience Corporation PD-L1 antibodies and uses thereof
WO2015195163A1 (en) 2014-06-20 2015-12-23 R-Pharm Overseas, Inc. Pd-l1 antagonist fully human antibody
TWI693232B (zh) 2014-06-26 2020-05-11 美商宏觀基因股份有限公司 與pd-1和lag-3具有免疫反應性的共價結合的雙抗體和其使用方法
WO2016000619A1 (en) 2014-07-03 2016-01-07 Beigene, Ltd. Anti-pd-l1 antibodies and their use as therapeutics and diagnostics
JO3663B1 (ar) 2014-08-19 2020-08-27 Merck Sharp & Dohme الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين
CU20170052A7 (es) 2014-10-14 2017-11-07 Dana Farber Cancer Inst Inc Moléculas de anticuerpo que se unen a pd-l1
LT3215532T (lt) 2014-11-06 2020-01-10 F. Hoffmann-La Roche Ag Anti-tim3 antikūnai ir jų naudojimo būdai
TWI595006B (zh) 2014-12-09 2017-08-11 禮納特神經系統科學公司 抗ｐｄ－１抗體類和使用彼等之方法
WO2016111947A2 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
EP3265486A4 (en) 2015-03-06 2018-11-14 Sorrento Therapeutics, Inc. Antibody therapeutics that bind tim3
MA41867A (fr) 2015-04-01 2018-02-06 Anaptysbio Inc Anticorps dirigés contre l'immunoglobuline de cellule t et protéine 3 de mucine (tim-3)
WO2017148391A1 (zh) * 2016-03-01 2017-09-08 上海医药集团股份有限公司 一种含氮杂环化合物、制备方法、中间体、组合物和应用
JP2021104931A (ja) 2018-02-22 2021-07-26 大日本住友製薬株式会社 含窒素複素環を有するジベンゾアゼピン誘導体
PE20240327A1 (es) * 2021-04-13 2024-02-22 Nuvalent Inc Heterociclos con sustitucion amino para tratar canceres con mutaciones de egfr

Also Published As

Publication number Publication date
AU2022257621A1 (en) 2023-11-23
IL306100A (en) 2023-11-01
KR20230170039A (ko) 2023-12-18
PE20240327A1 (es) 2024-02-22
US20220363696A1 (en) 2022-11-17
WO2022221227A1 (en) 2022-10-20
CA3213079A1 (en) 2022-10-20
WO2022221227A9 (en) 2023-11-30
BR112023021111A2 (pt) 2023-12-19
JP2024516371A (ja) 2024-04-15
EP4323356A1 (en) 2024-02-21
TW202309022A (zh) 2023-03-01

Similar Documents

Publication Publication Date Title
CL2023003020A1 (es) Heterociclos con sustitución amino para tratar cánceres con mutaciones de egfr
BR112019024525A2 (pt) composto, sal farmaceuticamente aceitável e formulação farmacêutica de inibidores de kras c12c
CY1122566T1 (el) Παραγωγο 6,7,8,9-tetpaϋδpo-3h-πυραζολo[4,3-f] ισοκινολινης χρησιμο στη θεραπευτικη αντιμετωπιση του καρκινου
CO2019000386A2 (es) Compuestos heterocíclicos como inmunomoduladores
CR20190318A (es) Compuestos heterocíclicos como inmunomoduladores
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
EA201892075A1 (ru) Комбинации ингибиторов lsd1 для применения для лечения солидных опухолей
MX2020012165A (es) Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer.
EA201891494A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
EA201990187A1 (ru) Антипролиферационные средства на основе пиримидина
EA201891203A1 (ru) Гетероциклические соединения в качестве иммуномодуляторов
NZ752526A (en) Pyrrolobenzodiazepine conjugates
EA201891229A1 (ru) Eif4a-ингибирующие соединения и связанные с ними способы
CL2022003046A1 (es) Agentes quimioterapéuticos de éteres macrocíclicos heteroaromáticos
EA202090497A1 (ru) Соединения и композиции для лечения гематологических нарушений
PH12019501896A1 (en) Therapeutic dendrimers
EA202192905A1 (ru) Соединения, содержащие n-метил-2-пиридон, и фармацевтически приемлемые соли
BR112018068412A2 (pt) composto, composição farmacêutica, método de tratamento de síndrome mielodisplásica e método para matar uma célula tumoral
CY1125126T1 (el) Θεραπεια συνδυασμου αναστολεα βρωμοεπικρατειας και επιπλεον-τερματικης πρωτεϊνης
CO2020013968A2 (es) Derivados de pladeniolida como agentes dirigidos a empalmosoma para tratar el cáncer
ZA201808562B (en) Phthalazine derivatives as inhibitors of parp1, parp2 and/or tubulin useful for the treatment of cancer
MX2015010619A (es) Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer.
MX2020003126A (es) Derivados de iminopirimidina ciclicos como inhibidores de cinasa.
PH12020551343A1 (en) 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer
PE20211268A1 (es) Proceso para preparar el benzotiofen-2-il boronato